PE20142448A1 - Compuestos de n-alquiltriazol como antagonistas de lpar - Google Patents
Compuestos de n-alquiltriazol como antagonistas de lparInfo
- Publication number
- PE20142448A1 PE20142448A1 PE2014002232A PE2014002232A PE20142448A1 PE 20142448 A1 PE20142448 A1 PE 20142448A1 PE 2014002232 A PE2014002232 A PE 2014002232A PE 2014002232 A PE2014002232 A PE 2014002232A PE 20142448 A1 PE20142448 A1 PE 20142448A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- alkyltriazole
- lpar
- antagonists
- triazol
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 title abstract 3
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 title abstract 3
- 239000005557 antagonist Substances 0.000 title abstract 2
- -1 3-TRIFLUOROMETHYL-PHENYL Chemical class 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661961P | 2012-06-20 | 2012-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20142448A1 true PE20142448A1 (es) | 2015-01-28 |
Family
ID=48628667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014002232A PE20142448A1 (es) | 2012-06-20 | 2013-06-17 | Compuestos de n-alquiltriazol como antagonistas de lpar |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9321738B2 (enExample) |
| EP (1) | EP2864300A1 (enExample) |
| JP (1) | JP2015520202A (enExample) |
| KR (1) | KR20150021057A (enExample) |
| CN (1) | CN104411692A (enExample) |
| AU (1) | AU2013279512A1 (enExample) |
| BR (1) | BR112014030685A2 (enExample) |
| CA (1) | CA2869541A1 (enExample) |
| CL (1) | CL2014003243A1 (enExample) |
| CO (1) | CO7131358A2 (enExample) |
| CR (1) | CR20140525A (enExample) |
| EA (1) | EA201492285A1 (enExample) |
| HK (1) | HK1206342A1 (enExample) |
| IL (1) | IL236088A0 (enExample) |
| IN (1) | IN2014DN09348A (enExample) |
| MA (1) | MA37764A1 (enExample) |
| MX (1) | MX2014014710A (enExample) |
| PE (1) | PE20142448A1 (enExample) |
| PH (1) | PH12014502789A1 (enExample) |
| SG (1) | SG11201407220YA (enExample) |
| UA (1) | UA109868C2 (enExample) |
| WO (1) | WO2013189864A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012296662A1 (en) | 2011-08-15 | 2014-03-27 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| JP2015520203A (ja) * | 2012-06-20 | 2015-07-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｌｐａｒ拮抗薬としてのｎ−アリールトリアゾール化合物 |
| US10000459B2 (en) | 2013-03-15 | 2018-06-19 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| AU2015281021B9 (en) | 2014-06-27 | 2019-03-28 | Ube Corporation | Salt of halogen-substituted heterocyclic compound |
| AR108838A1 (es) * | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| KR102698386B1 (ko) | 2017-12-19 | 2024-08-22 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 피라졸 n-연결된 카르바모일 시클로헥실 산 |
| WO2019126103A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azoles as lpa antagonists |
| CN112074515B (zh) | 2017-12-19 | 2025-01-10 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸异噁唑唑类 |
| JP7202383B2 (ja) | 2017-12-19 | 2023-01-11 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸 |
| TW202017918A (zh) * | 2017-12-19 | 2020-05-16 | 美商必治妥美雅史谷比公司 | 作為lpa拮抗劑之環己基酸三唑吖 |
| JP7526096B2 (ja) * | 2017-12-19 | 2024-07-31 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン |
| KR102697358B1 (ko) | 2017-12-19 | 2024-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 이속사졸 o-연결된 카르바모일 시클로헥실 산 |
| EP3728210B1 (en) | 2017-12-19 | 2026-02-11 | Bristol-Myers Squibb Company | Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| US10662172B2 (en) * | 2017-12-19 | 2020-05-26 | Bristol-Myers Squibb Company | Triazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
| KR20200100713A (ko) * | 2017-12-19 | 2020-08-26 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 트리아졸 아졸 |
| US11312706B2 (en) | 2017-12-19 | 2022-04-26 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as LPA antagonists |
| IL297802A (en) * | 2017-12-29 | 2022-12-01 | Biomarin Pharm Inc | Glycolate oxidase inhibitors to treat the disease |
| ES2946657T3 (es) * | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
| ES2948793T3 (es) * | 2018-09-18 | 2023-09-19 | Bristol Myers Squibb Co | Acidos cicloheptílicos como antagonistas de LPA |
| CN113366000A (zh) * | 2018-09-18 | 2021-09-07 | 百时美施贵宝公司 | 作为lpa拮抗剂的氧杂双环酸 |
| EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| KR102913125B1 (ko) | 2020-06-03 | 2026-01-20 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| CA3218917A1 (en) | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2022241023A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR20240115978A (ko) | 2021-12-08 | 2024-07-26 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| AR128613A1 (es) | 2022-02-25 | 2024-05-29 | Lhotse Bio Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| GB2466121B (en) * | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) * | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
| GB2474748B (en) * | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| WO2011159550A2 (en) * | 2010-06-14 | 2011-12-22 | Amidra Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist and uses thereof |
| WO2011159633A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| PH12013501136A1 (en) * | 2010-12-07 | 2013-07-08 | Amira Pharmaceuticals Inc | Lysophosphatidic acid receptor antagonists and uses thereof |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| AU2012296662A1 (en) * | 2011-08-15 | 2014-03-27 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
-
2013
- 2013-06-17 EA EA201492285A patent/EA201492285A1/ru unknown
- 2013-06-17 US US14/401,009 patent/US9321738B2/en not_active Expired - Fee Related
- 2013-06-17 JP JP2015517704A patent/JP2015520202A/ja not_active Ceased
- 2013-06-17 MA MA37764A patent/MA37764A1/fr unknown
- 2013-06-17 MX MX2014014710A patent/MX2014014710A/es unknown
- 2013-06-17 CA CA2869541A patent/CA2869541A1/en not_active Abandoned
- 2013-06-17 KR KR1020147035768A patent/KR20150021057A/ko not_active Ceased
- 2013-06-17 IN IN9348DEN2014 patent/IN2014DN09348A/en unknown
- 2013-06-17 CN CN201380032285.0A patent/CN104411692A/zh active Pending
- 2013-06-17 WO PCT/EP2013/062461 patent/WO2013189864A1/en not_active Ceased
- 2013-06-17 HK HK15106927.8A patent/HK1206342A1/xx unknown
- 2013-06-17 SG SG11201407220YA patent/SG11201407220YA/en unknown
- 2013-06-17 EP EP13729330.4A patent/EP2864300A1/en not_active Withdrawn
- 2013-06-17 AU AU2013279512A patent/AU2013279512A1/en not_active Abandoned
- 2013-06-17 PE PE2014002232A patent/PE20142448A1/es not_active Application Discontinuation
- 2013-06-17 UA UAA201500428A patent/UA109868C2/ru unknown
- 2013-06-17 BR BR112014030685A patent/BR112014030685A2/pt not_active Application Discontinuation
-
2014
- 2014-11-17 CR CR20140525A patent/CR20140525A/es unknown
- 2014-11-21 CO CO14256136A patent/CO7131358A2/es unknown
- 2014-11-28 CL CL2014003243A patent/CL2014003243A1/es unknown
- 2014-12-04 IL IL236088A patent/IL236088A0/en unknown
- 2014-12-15 PH PH12014502789A patent/PH12014502789A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2014DN09348A (enExample) | 2015-07-17 |
| CO7131358A2 (es) | 2014-12-01 |
| CA2869541A1 (en) | 2013-12-27 |
| CL2014003243A1 (es) | 2015-03-20 |
| PH12014502789A1 (en) | 2015-02-09 |
| EA201492285A1 (ru) | 2015-04-30 |
| CR20140525A (es) | 2015-01-12 |
| MX2014014710A (es) | 2015-03-04 |
| SG11201407220YA (en) | 2014-12-30 |
| UA109868C2 (ru) | 2015-10-12 |
| IL236088A0 (en) | 2015-02-01 |
| KR20150021057A (ko) | 2015-02-27 |
| HK1206342A1 (en) | 2016-01-08 |
| JP2015520202A (ja) | 2015-07-16 |
| BR112014030685A2 (pt) | 2017-06-27 |
| EP2864300A1 (en) | 2015-04-29 |
| US9321738B2 (en) | 2016-04-26 |
| CN104411692A (zh) | 2015-03-11 |
| MA37764A1 (fr) | 2016-01-29 |
| AU2013279512A1 (en) | 2014-10-16 |
| WO2013189864A1 (en) | 2013-12-27 |
| US20150133511A1 (en) | 2015-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20142448A1 (es) | Compuestos de n-alquiltriazol como antagonistas de lpar | |
| PE20142305A1 (es) | Compuestos de n-ariltriazol como antagonistas de lpar | |
| PE20170502A1 (es) | ACIDO 4-(3-FLUORO-3-(2-(5,6,7,8-TETRAHIDRO-1,8-NAFTIRIDIN-2-IL)ETIL)PIRROLIDIN-1-IL)-3-(3-(2-METOXIETOXI)FENIL)BUTANOICO COMO ANTAGONISTA DE INTEGRINA aVß6 | |
| PE20190211A1 (es) | Acidos de carbamoiloximetil triazol ciclohexilo como antagonistas de acido lisofosfatidico (lpa) | |
| PE20142301A1 (es) | Uracilos sustituidos biciclicamente y uso de los mismos | |
| UA112317C2 (uk) | Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину | |
| MX2012008361A (es) | Compuestos de pirazol como antagonistas de crth2. | |
| UY32327A (es) | Antagonistas de receptores de ácido lisofosfatídico | |
| CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
| CL2011002706A1 (es) | Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras. | |
| CR20140057A (es) | Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-etoxi-etil}-1h-[1,2,4]triazol sustituidos | |
| CL2011003072A1 (es) | Compuestos derivados de 4´-(isoxazol-5-il)-bifenil-4-il-cicloalquil(c3-8), antagonistas del receptor de acido lisofosfatidico; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, problemas pulmonares, entre otras. | |
| MA34069B1 (fr) | Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a) | |
| TR201904455T4 (tr) | Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları. | |
| CL2008003181A1 (es) | Sal del acido 3-[5-(piridin-2-il-metoxi)-3-(2-metil-2-propiltio)-1-[4-(2-metoxipiridin-5-il)bencil]-indol-2-il]-2,2-dimetil-propionico; fromas crsitalinas de la sal sodica; proceso de preparacion; composiciones farmaceuticas; kit farmaceutico, y uso para el tratamiento de asma. | |
| EA201591662A1 (ru) | Липиды и липидные композиции для доставки активных агентов | |
| MX354102B (es) | Derivados de bencimidazol-prolina. | |
| CR20140038A (es) | Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alquiniloxi-etil}-1h-[1,2,4]triazol sustituidos | |
| CL2011003147A1 (es) | Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer. | |
| PH12014502364A1 (en) | Substituted pyrazole compounds as lpar antagonists | |
| CL2018000057A1 (es) | Composiciones farmacéuticas que comprenden un antagonista de la integrina alfa4 para uso en el tratamiento de afecciones inflamatorias oculares | |
| PE20160846A1 (es) | Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c | |
| MX364610B (es) | Derivados de 1- [m-carboxamido (hetero) aril-metil]-heterociclil-c arboxamida. | |
| EA201600435A1 (ru) | Кристаллическая форма (s)-(2-(6-хлор-7-метил-1н-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора | |
| MX378947B (es) | Composición farmacéutica estable para administración oral. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |